Donor Alloantigen Reactive Tregs (National Institute of Allergy and Infectious Diseases)

N/A

Report date: 2024/12/16 20:00:57

Base Information

Drug NameDonor Alloantigen Reactive Tregs (National Institute of Allergy and Infectious Diseases)

Drug Alias NameDonor Alloantigen Reactive T regulatory cells供体抗原的反应性T细胞-国家过敏和传染病研究所darTregs

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TregsCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsRejection of liver transplantation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

Active IndicationsN/A

Inactive IndicationsRejection of liver transplantation

Other Information

ATC CodeN/A